Related Experiment Video
Updated: Jan 26, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Biology and therapy of multiple myeloma
Douglas E Joshua1, Christian Bryant1, Caroline Dix1
1Royal Prince Alfred Hospital, Sydney, NSW.
Abstract:
Genetic sequencing of the myeloma genome has not revealed a specific disease-determining genetic alteration. Multiple disease subclones exist at diagnosis and vary in clinical importance with time and drug sensitivity. New diagnostic criteria have identified indications for early introduction of therapy. Autologous stem cell transplantation remains an essential component of therapy in young and fit patients. The use of continual suppressive (maintenance) therapy has been established as an important component in therapy. Immune therapies and the harnessing of the innate immune system offer great promise for future treatments. Since 2005, quality of life, supportive therapies, and survival have dramatically improved over a decade of remarkable progress. The common manifestations of multiple myeloma, such as bone pain, fatigue and weight loss, may be non-specific and are often initially ignored or missed by patients and medical practitioners.
Insights
Multiple myeloma lacks a single genetic driver, featuring diverse subclones impacting treatment. Advances since 2005 have significantly improved patient quality of life, supportive care, and survival rates.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Multiple myeloma diagnosis is complicated by the absence of a specific genetic alteration.
- The disease presents with multiple subclones that evolve, influencing treatment sensitivity and clinical outcomes.
- Early diagnostic criteria now support prompt therapeutic intervention.
Purpose of the Study:
- To review the current understanding of multiple myeloma genetics and disease heterogeneity.
- To highlight advancements in diagnostic criteria and therapeutic strategies.
- To discuss the evolving landscape of multiple myeloma treatment and patient outcomes.
Main Methods:
- Review of genetic sequencing data for multiple myeloma.
- Analysis of clinical data regarding disease progression and subclone dynamics.
- Evaluation of therapeutic outcomes including stem cell transplantation and maintenance therapy.
Main Results:
- No single genetic alteration defines multiple myeloma; diverse subclones are present at diagnosis.
- Early therapy introduction is now indicated based on new diagnostic criteria.
- Autologous stem cell transplantation and maintenance therapy are key treatment components.
- Significant improvements in quality of life, supportive care, and survival observed since 2005.
Conclusions:
- Multiple myeloma is characterized by genetic heterogeneity, necessitating personalized treatment approaches.
- Ongoing research into immune therapies and innate immune system modulation holds promise for future treatments.
- Recent therapeutic progress has dramatically enhanced patient outcomes and quality of life.
Related Concept Videos
01:57What is Conservation Biology?
01:49Multiple Allele Traits
00:59Gene Therapy
02:59Biological Effects of Radiation
01:25Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
01:26Group Therapy